Literature DB >> 25503303

Identification of two glioblastoma-associated stromal cell subtypes with different carcinogenic properties in histologically normal surgical margins.

Anne Clavreul1, Amandine Etcheverry, Clément Tétaud, Audrey Rousseau, Tony Avril, Cécile Henry, Jean Mosser, Philippe Menei.   

Abstract

Glioblastoma (GB) is a highly infiltrative tumor recurring within a few centimeters of the resection cavity in 85 % of cases, even in cases of complete tumor resection and adjuvant chemo/radiotherapy. We recently isolated GB-associated stromal cells (GASCs) from the GB peritumoral zone, with phenotypic and functional properties similar to those of the cancer-associated fibroblasts present in the stroma of carcinomas. In particular, GASCs promote blood vessel development and have tumor-promoting effects on glioma cells in vitro and in vivo. In this study, we characterized these cells further, by analyzing the transcriptome and methylome of 14 GASC and five control stromal cell preparations derived from non-GB peripheral brain tissues. We identified two subtypes of GASCs in surgical margins in GB patients: GASC-A and GASC-B. GASC-B promoted the development of tumors and endothelium, whereas GASC-A did not. A difference in DNA methylation may underlie these two subtypes. We identified various proteins as being produced in the procarcinogenic GASC-B. Some of these proteins may serve as prognostic factors for GB and/or targets for anti-glioma treatment. In conclusion, in this era of personalized therapy, the status of GASCs in GB-free surgical margins should be taken into account, to improve treatment and the prevention of recurrence.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25503303     DOI: 10.1007/s11060-014-1683-z

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  40 in total

1.  The influence of surgery on recurrence pattern of glioblastoma.

Authors:  Pasquale De Bonis; Carmelo Anile; Angelo Pompucci; Alba Fiorentino; Mario Balducci; Silvia Chiesa; Libero Lauriola; Giulio Maira; Annunziato Mangiola
Journal:  Clin Neurol Neurosurg       Date:  2012-04-24       Impact factor: 1.876

2.  Global hypomethylation of genomic DNA in cancer-associated myofibroblasts.

Authors:  Le Jiang; Tamas A Gonda; Mary V Gamble; Martha Salas; Venkatraman Seshan; Shuiping Tu; William S Twaddell; Peter Hegyi; Gyorgy Lazar; Islay Steele; Andrea Varro; Timothy C Wang; Benjamin Tycko
Journal:  Cancer Res       Date:  2008-12-01       Impact factor: 12.701

3.  Distinct epigenetic changes in the stromal cells of breast cancers.

Authors:  Min Hu; Jun Yao; Li Cai; Kurt E Bachman; Frédéric van den Brûle; Victor Velculescu; Kornelia Polyak
Journal:  Nat Genet       Date:  2005-07-10       Impact factor: 38.330

Review 4.  What is the clinical value of cancer stem cell markers in gliomas?

Authors:  Rikke Hedegaard Dahlrot; Simon Kjær Hermansen; Steinbjørn Hansen; Bjarne Winther Kristensen
Journal:  Int J Clin Exp Pathol       Date:  2013-02-15

5.  Glioblastoma-associated stromal cells (GASCs) from histologically normal surgical margins have a myofibroblast phenotype and angiogenic properties.

Authors:  Anne Clavreul; Catherine Guette; Rogatien Faguer; Clément Tétaud; Alice Boissard; Laurent Lemaire; Audrey Rousseau; Tony Avril; Cécile Henry; Olivier Coqueret; Philippe Menei
Journal:  J Pathol       Date:  2014-02-20       Impact factor: 7.996

6.  Assessment of angiogenesis by CD105 and nestin expression in peritumor tissue of glioblastoma.

Authors:  Gigliola Sica; Gina Lama; Carmelo Anile; Maria Concetta Geloso; Giuseppe La Torre; Pasquale De Bonis; Giulio Maira; Libero Lauriola; Meena Jhanwar-Uniyal; Annunziato Mangiola
Journal:  Int J Oncol       Date:  2011-01       Impact factor: 5.650

7.  Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.

Authors:  Roger Stupp; Monika E Hegi; Warren P Mason; Martin J van den Bent; Martin J B Taphoorn; Robert C Janzer; Samuel K Ludwin; Anouk Allgeier; Barbara Fisher; Karl Belanger; Peter Hau; Alba A Brandes; Johanna Gijtenbeek; Christine Marosi; Charles J Vecht; Karima Mokhtari; Pieter Wesseling; Salvador Villa; Elizabeth Eisenhauer; Thierry Gorlia; Michael Weller; Denis Lacombe; J Gregory Cairncross; René-Olivier Mirimanoff
Journal:  Lancet Oncol       Date:  2009-03-09       Impact factor: 41.316

Review 8.  CD146, a multi-functional molecule beyond adhesion.

Authors:  Zhaoqing Wang; Xiyun Yan
Journal:  Cancer Lett       Date:  2012-12-21       Impact factor: 8.679

Review 9.  Myofibroblasts.

Authors:  Biao Hu; Sem H Phan
Journal:  Curr Opin Rheumatol       Date:  2013-01       Impact factor: 5.006

Review 10.  Carcinoma-associated fibroblasts: non-neoplastic tumour-promoting mesenchymal cells.

Authors:  Urszula M Polanska; Akira Orimo
Journal:  J Cell Physiol       Date:  2013-08       Impact factor: 6.384

View more
  9 in total

1.  Expression of pituitary tumor-transforming 2 in human glioblastoma cell lines and its role in glioblastoma tumorigenesis.

Authors:  Yunbao Guo; Yimeng Shao; Jing Chen; Songbai Xu; Xingdong Zhang; Haiyan Liu
Journal:  Exp Ther Med       Date:  2016-03-15       Impact factor: 2.447

Review 2.  Intratumoral heterogeneity in glioblastoma: don't forget the peritumoral brain zone.

Authors:  Jean-Michel Lemée; Anne Clavreul; Philippe Menei
Journal:  Neuro Oncol       Date:  2015-07-22       Impact factor: 12.300

3.  Virus vector-mediated genetic modification of brain tumor stromal cells after intravenous delivery.

Authors:  Adrienn Volak; Stanley G LeRoy; Jeya Shree Natasan; David J Park; Pike See Cheah; Andreas Maus; Zachary Fitzpatrick; Eloise Hudry; Kelsey Pinkham; Sheetal Gandhi; Bradley T Hyman; Dakai Mu; Dwijit GuhaSarkar; Anat O Stemmer-Rachamimov; Miguel Sena-Esteves; Christian E Badr; Casey A Maguire
Journal:  J Neurooncol       Date:  2018-05-16       Impact factor: 4.130

4.  Integration of transcriptome and proteome profiles in glioblastoma: looking for the missing link.

Authors:  Jean-Michel Lemée; Anne Clavreul; Marc Aubry; Emmanuelle Com; Marie de Tayrac; Jean Mosser; Philippe Menei
Journal:  BMC Mol Biol       Date:  2018-11-21       Impact factor: 2.946

5.  The French glioblastoma biobank (FGB): a national clinicobiological database.

Authors:  Anne Clavreul; Gwénaëlle Soulard; Jean-Michel Lemée; Marion Rigot; Pascale Fabbro-Peray; Luc Bauchet; Dominique Figarella-Branger; Philippe Menei
Journal:  J Transl Med       Date:  2019-04-23       Impact factor: 5.531

Review 6.  Mesenchymal Stromal-Like Cells in the Glioma Microenvironment: What Are These Cells?

Authors:  Anne Clavreul; Philippe Menei
Journal:  Cancers (Basel)       Date:  2020-09-15       Impact factor: 6.639

7.  Blood-brain barrier alterations in human brain tumors revealed by genome-wide transcriptomic profiling.

Authors:  Johanna Schaffenrath; Tania Wyss; Liqun He; Elisabeth Jane Rushing; Mauro Delorenzi; Flavio Vasella; Luca Regli; Marian Christoph Neidert; Annika Keller
Journal:  Neuro Oncol       Date:  2021-12-01       Impact factor: 12.300

8.  Human mesenchymal stromal cells as cellular drug-delivery vectors for glioblastoma therapy: a good deal?

Authors:  Anne Clavreul; Milad Pourbaghi-Masouleh; Emilie Roger; Nolwenn Lautram; Claudia N Montero-Menei; Philippe Menei
Journal:  J Exp Clin Cancer Res       Date:  2017-09-29

9.  Impact of mesenchymal stem cells' secretome on glioblastoma pathophysiology.

Authors:  Joana Vieira de Castro; Eduardo D Gomes; Sara Granja; Sandra I Anjo; Fátima Baltazar; Bruno Manadas; António J Salgado; Bruno M Costa
Journal:  J Transl Med       Date:  2017-10-02       Impact factor: 5.531

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.